ShareValue scores for FRE.AU: Valuation 37, Quality 13, Growth 61, Health 66.
FRE.AUASX
Firebrick Pharma Ltd
A$0.03
(-6.06%)
FRE.AUASX
Firebrick Pharma Ltd
A$0.03(-6.06%)
Loading chart...
Sentiment
Verdicts
Value:Overvalued
Quality:Weak
Growth:Moderate
Health:Moderate
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
-7% to 13%
Rating
Trap Risk
Return
-7% to 13%
Valuation
37
Overvalued
Price vs Value
Quality
13
Weak
Business Strength
Growth
61
Moderate
Revenue & Earnings
Health
66
Moderate
Financial Stability
Momentum
19
Bearish
Price Trend
Company Details
About
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.
Market Cap$9M
P/E Ratio-2.0
Dividend YieldNone
Sector Rank#1817
Score Analysis
AI Investment Thesis
Data as of:Jul 9, 2026
|Last calculated:Jul 9, 2026